Table 2 CDH22 hypermethylation in our series of patients
From: CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
Parameter | Number |
|---|---|
Breast tumours | n = 142 |
Median % CpG1 methylation (range) | 9.0 (1–100) |
Median % CpG4 methylation (range) | 58.0 (0–74) |
Median % CpG5 methylation (range) | 65.0 (2–98) |
Adjacent-to-tumour tissues | n = 26 |
Median % CpG1 methylation (range) | 2.0 (0–98) |
Median % CpG4 methylation (range) | 9.0 (0–57) |
Median % CpG5 methylation (range) | 28.0 (3–70) |
Non-neoplastic breast samples | n = 19 |
Median % CpG1 methylation (range) | 5.0 (0–27) |
Median % CpG4 methylation (range) | 8.0 (0–33) |
Median % CpG5 methylation (range) | 9.5 (3–30) |
Cut-off values (%) | |
CpG1 | 17.5 |
CpG4 | 40.0 |
CpG5 | 66.5 |